TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10895224

Group type: EXPERIMENTAL
Intervention: Treadmill exercise (TD)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bicycle ergometer exercise (BE)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Submaximal exercise on BE
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Maximal exercise on TD
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Rate of perceived exertion
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Preference for exercise mode
Number of subjects: 60
Study: 8320925

Group type: EXPERIMENTAL
Intervention: Cuprophane
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Cellulose acetate
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Polymethylmethacrylate
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Polysulphone
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: AN-69
Number of subjects: 9
Study: 3091543

Group type: EXPERIMENTAL
Intervention: Nutrition education (home-based nutrition counselling sessions for mothers/caretakers)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 65
Study: 30172995

Group type: EXPERIMENTAL
Intervention: Phospholipid intake (2.7 g/d for 6 weeks)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 54
Study: 28432157

Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study: 26310452

Group type: EXPERIMENTAL
Intervention: Telemedicine-based CPAP follow-up strategy
Number of subjects: 139

Group type: COMPARATOR
Intervention: Standard face-to-face management
Number of subjects: 139
Study: 23430390

Group type: EXPERIMENTAL
Intervention: Mizoribine (MZR) at a starting dose of 12 mg/kg/day
Number of subjects: 35

Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF) at a starting dose of 2 g/day
Number of subjects: 35
Study: 20690864

Group type: EXPERIMENTAL
Intervention: 0.625 mg oral conjugated estrogens for 30 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo for 30 days
Number of subjects: 40
Study: 19699856

Group type: EXPERIMENTAL
Intervention: Algorithm-based care approach
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Health-promotion campaign
Number of subjects: 0
Study: 16916335

Group type: EXPERIMENTAL
Intervention: Usual care plus structured education on the use of a written self-management plan and patient-initiated short courses of antibiotics and oral corticosteroids
Number of subjects: 159

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 159
Study: 15315625

Group type: EXPERIMENTAL
Intervention: Dextromethorphan (DM) 40 mg IM and normal saline IV
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Dextromethorphan (DM) 40 mg IM and tenoxicam 40 mg IV
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Tenoxicam 40 mg IV
Number of subjects: 88

Group type: COMPARATOR
Intervention: Chlorpheniramine maleate (CPM) 20 mg IM and normal saline IV
Number of subjects: 88
Study: 11011670

Group type: EXPERIMENTAL
Intervention: Operative treatment
Number of subjects: 84

Group type: COMPARATOR
Intervention: Conservative treatment (non-operated group)
Number of subjects: 84
Study: 9076589

Group type: EXPERIMENTAL
Intervention: Osteoporosis-targeted quality of life questionnaire (OPTQoL)
Number of subjects: 465

Group type: COMPARATOR
Intervention: Standard generic questionnaire (SF-36)
Number of subjects: 465
Study: 8361796

Group type: EXPERIMENTAL
Intervention: Desmopressin acetate (DDAVP)
Number of subjects: 689

Group type: COMPARATOR
Intervention: Conditioning alarms
Number of subjects: 689
Study: 2871788

Group type: EXPERIMENTAL
Intervention: 6-month regimen of chemotherapy (streptomycin, isoniazid, rifampin, pyrazinamide for 2 months followed by isoniazid and rifampin)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: 4-month regimen of chemotherapy (streptomycin, isoniazid, rifampin, pyrazinamide for 2 months followed by isoniazid and rifampin)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Patients with bacilli resistant to isoniazid, streptomycin, or both drugs in the 6-month series
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Patients with bacilli resistant to isoniazid, streptomycin, or both drugs in the 4-month series
Number of subjects: 330
Study: 28822586

Group type: EXPERIMENTAL
Intervention: Mannitol (12.5g)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199
Study: 26921492

Group type: EXPERIMENTAL
Intervention: Baseline chest pain
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Numbness/tingling
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Depressive symptoms (Patient Health Questionnaire-9)
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Higher comorbidity count
Number of subjects: 384
Study: 25379847

Group type: EXPERIMENTAL
Intervention: NCRT
Number of subjects: 593

Group type: COMPARATOR
Intervention: Primary Surgery
Number of subjects: 593
Study: 21963681

Group type: EXPERIMENTAL
Intervention: Psycho-education group sessions (6 during pregnancy, 1 after childbirth)
Number of subjects: 355

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 355
Study: 20597857

Group type: EXPERIMENTAL
Intervention: Simulation-enhanced laboratory
Number of subjects: 53

Group type: COMPARATOR
Intervention: Traditional laboratory
Number of subjects: 53
Study: 17606671

Group type: EXPERIMENTAL
Intervention: Side-lying external rotation
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Side-lying forward flexion
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Prone horizontal abduction with external rotation
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Prone extension
Number of subjects: 45

Group type: COMPARATOR
Intervention: None of the exercises
Number of subjects: 45
Study: 15822041

Group type: EXPERIMENTAL
Intervention: Oral supplement enriched with fish oil, fructooligosaccharides, gum arabic, vitamin E, vitamin C, and selenium, 18 oz daily for 6 months
Number of subjects: 121

Group type: COMPARATOR
Intervention: Carbohydrate-based placebo formula, 18 oz daily for 6 months
Number of subjects: 121
Study: 12402011

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation of the palate (RFAP)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Laser-assisted uvulopalatoplasty (LAUP)
Number of subjects: 20
Study: 10192404

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 339

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Both Olanzapine and Risperidone
Number of subjects: 339
Study: 8520812

Group type: EXPERIMENTAL
Intervention: Morphine with naltrexone
Number of subjects: 0
Study: 1996763

Group type: EXPERIMENTAL
Intervention: Lignocaine 10 mg
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Procaine 10 mg
Number of subjects: 273

Group type: COMPARATOR
Intervention: Isotonic saline 0.5 ml (Control)
Number of subjects: 273
Study: 6853080

Group type: EXPERIMENTAL
Intervention: Autotransfusion
Number of subjects: 202
Study: 30478089

Group type: EXPERIMENTAL
Intervention: Haploidentical stem cell transplantation (haplo‐HSCT)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 147
Study: 30354627

Group type: EXPERIMENTAL
Intervention: NuMED Covered CP Stent (CCPS)
Number of subjects: 120
Study: 25045806

Group type: EXPERIMENTAL
Intervention: Non-adjuvanted vaccine
Number of subjects: 84

Group type: COMPARATOR
Intervention: Adjuvanted vaccine
Number of subjects: 84
Study: 22334769

Group type: EXPERIMENTAL
Intervention: Mometasone furoate/formoterol fumarate (MF/F) 400/10 μg
Number of subjects: 1196

Group type: EXPERIMENTAL
Intervention: Mometasone furoate/formoterol fumarate (MF/F) 200/10 μg
Number of subjects: 1196

Group type: COMPARATOR
Intervention: Mometasone furoate (MF) 400 μg
Number of subjects: 1196

Group type: COMPARATOR
Intervention: Formoterol (F) 10 μg
Number of subjects: 1196

Group type: EXPERIMENTAL
Intervention: Mometasone furoate/formoterol fumarate (MF/F)
Number of subjects: 1196

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1196
Study: 19179917

Group type: EXPERIMENTAL
Intervention: Nonresorbable poly-ether-ether-ketone (PEEK) cage
Number of subjects: 26

Group type: COMPARATOR
Intervention: Resorbable poly-L-lactide-co-D,L-lactide (PLDLLA) cage
Number of subjects: 26
Study: 17690198

Group type: EXPERIMENTAL
Intervention: beta-alanine (4.8 g/day)
Number of subjects: 15

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 15
Study: 15383109

Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 80

Group type: COMPARATOR
Intervention: Bupivicaine/Fentanyl
Number of subjects: 80
Study: 11420346

Group type: EXPERIMENTAL
Intervention: HandClens (alcohol-free antiseptic hand wash)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Purell (alcohol-based product)
Number of subjects: 40
Study: 9043028

Group type: EXPERIMENTAL
Intervention: Recombinant human interleukin 3 (rhIL‐3) 10 microg kg(‐1) day(‐1) (days 5‐9) + G‐CSF 5.0 microg kg(‐1) day(‐1) (days 7‐16)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Paclitaxel (135 mg m(‐2) day 1), ifosfamide (1.2 g m(‐2) day(‐1) days 2-4), cisplatin (30 mg m(‐2) day(‐1) days 2-4) + G‐CSF 5.0 microg kg(‐1) day(‐1) (days 7-16)
Number of subjects: 16
Study: 7639381

Group type: COMPARATOR
Intervention: Normal saline IV and epidurally (Control Group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1 mg/kg of 2% lidocaine IV as a bolus (Group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg of 2% lidocaine IV for 5 min (Group C)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1 mg/kg of 2% lidocaine IV for 5 min (Group D)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 3 mg/kg of 1.5% lidocaine epidurally as a bolus (Group E)
Number of subjects: 60
Study: 3235818

Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Alpidem (50 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Alpidem (25 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Alcohol + Lorazepam
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Alcohol + Alpidem (50 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Alcohol + Alpidem (25 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Alcohol + Placebo
Number of subjects: 12
Study: 29893482

Group type: EXPERIMENTAL
Intervention: MEDiPORT cognitive-behavioral arm (robot using evidence-based cognitive-behavioral interventions)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Active distraction arm (robot dancing and singing)
Number of subjects: 40
Study: 26659384

Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl injection
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (Normotensive men)
Number of subjects: 8
Study: 25149384

Group type: EXPERIMENTAL
Intervention: Yinxieling decoction (8 weeks treatment)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (8 weeks treatment)
Number of subjects: 120
Study: 23129602

Group type: EXPERIMENTAL
Intervention: AMG 145 350 mg
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: AMG 145 420 mg
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study: 20826719

Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 600

Group type: COMPARATOR
Intervention: Fluconazole
Number of subjects: 600
Study: 18093356

Group type: EXPERIMENTAL
Intervention: Bispectral index monitoring
Number of subjects: 126

Group type: COMPARATOR
Intervention: No bispectral index monitoring
Number of subjects: 126
Study: 16022920

Group type: EXPERIMENTAL
Intervention: Topotecan 1.25 mg/(m² day) IV days 1-5, cisplatin 50 mg/m² IV day 5 (T/C)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Topotecan 0.75 mg/(m² day) IV days 1-5, etoposide 60 mg/(m² day) IV days 1-5 (T/E)
Number of subjects: 82
Study: 12675729

Group type: EXPERIMENTAL
Intervention: 100 mg of elemental Fe per day
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 11199506

Group type: EXPERIMENTAL
Intervention: PDE III inhibitor (amrinone, 1 mg/kg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no PDE III inhibitor)
Number of subjects: 16
Study: 8887212

Group type: EXPERIMENTAL
Intervention: 20 min of self-selected exercise in a student gymnasium
Number of subjects: 17

Group type: COMPARATOR
Intervention: 20 min of rest in a neutral setting (laboratory)
Number of subjects: 17
Study: 1728484

Group type: EXPERIMENTAL
Intervention: 10 mg amrinone
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 20 microg digoxin (infused over 20 minutes)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 10 mg amrinone (after digoxin infusion)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (instead of digoxin)
Number of subjects: 14
Study: 6374931

Group type: EXPERIMENTAL
Intervention: Sotalol hydrochloride 160 mg/d plus hydrochlorothiazide 25 mg/d
Number of subjects: 50

Group type: COMPARATOR
Intervention: Reserpine 0.1 mg/d plus hydrochlorothiazide 25 mg/d
Number of subjects: 50
Study: 31721757

Group type: EXPERIMENTAL
Intervention: Femoral Obturator Nerve Block (FONB)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Fascia Iliaca Compartment Block (FICB)
Number of subjects: 154
Study: 29697150

Group type: EXPERIMENTAL
Intervention: Preventive weights
Number of subjects: 846

Group type: EXPERIMENTAL
Intervention: Diagnostic weights
Number of subjects: 846

Group type: EXPERIMENTAL
Intervention: Ratings of components of responsibility
Number of subjects: 846

Group type: EXPERIMENTAL
Intervention: Mental effort, invasiveness, dexterity, experience, and knowledge
Number of subjects: 846
Study: 26684472

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Applied Relaxation (AR)
Number of subjects: 60
Study: 24615217

Group type: EXPERIMENTAL
Intervention: Proactive care (proactive outreach and offer of choice of smoking cessation services)
Number of subjects: 6400

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 6400

Group type: EXPERIMENTAL
Intervention: Proactive care
Number of subjects: 6400
Study: 22995464

Group type: EXPERIMENTAL
Intervention: Royal Jelly (RJ) 3000 mg in 100 ml liquid/day for 6 months
Number of subjects: 61
Study: 19756814

Group type: EXPERIMENTAL
Intervention: Cardiac magnetic resonance first pass perfusion imaging (CMR‐FPPI)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Cardiac magnetic resonance first pass perfusion imaging (CMR‐FPPI) in females
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Cardiac magnetic resonance first pass perfusion imaging (CMR‐FPPI) in males
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Cardiac magnetic resonance first pass perfusion imaging (CMR‐FPPI) in females with suspected primary CAD
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Cardiac magnetic resonance first pass perfusion imaging (CMR‐FPPI) in females with suspected progression
Number of subjects: 256
Study: 18070745

Group type: EXPERIMENTAL
Intervention: Intensive instructor‐led intervention (ILI)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Self‐help (SH)
Number of subjects: 80
Study: 16270862

Group type: EXPERIMENTAL
Intervention: Four different methods of travel in an immersive virtual environment (IVE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Large tracked space allowing participants to walk around the virtual environment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Steed‐Usoh‐Slater Presence Questionnaire
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Path analysis of logged position and head orientation data
Number of subjects: 0
Study: 12145577

Group type: EXPERIMENTAL
Intervention: Laparoscopic CBD exploration and cholecystectomy (Group A)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Endoscopic stone extraction and laparoscopic cholecystectomy (Group B)
Number of subjects: 78
Study: 10213716

Group type: EXPERIMENTAL
Intervention: Adrenaline
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Dopexamine
Number of subjects: 138

Group type: COMPARATOR
Intervention: Routine perioperative care (Control)
Number of subjects: 138
Study: 8544420

Group type: EXPERIMENTAL
Intervention: methylprednisolone and chlorambucil
Number of subjects: 81

Group type: COMPARATOR
Intervention: symptomatic therapy
Number of subjects: 81
Study: 2364165

Group type: EXPERIMENTAL
Intervention: Chromosomal translocations (specifically t(1;19)(q23;p13)) in pre-B ALL
Number of subjects: 964

Group type: EXPERIMENTAL
Intervention: Chromosomal translocations (specifically t(1;19)(q23;p13)) in early pre-B ALL
Number of subjects: 964

Group type: EXPERIMENTAL
Intervention: t(1;19)(q23;p13) in pre-B ALL
Number of subjects: 964

Group type: COMPARATOR
Intervention: Other translocations in pre-B ALL
Number of subjects: 964

Group type: COMPARATOR
Intervention: Any other karyotypic abnormality in pre-B ALL
Number of subjects: 964
Study: 737427

Group type: EXPERIMENTAL
Intervention: Intraperitoneal drain inserted
Number of subjects: 103

Group type: COMPARATOR
Intervention: No intraperitoneal drain
Number of subjects: 103
Study: 30521656

Group type: EXPERIMENTAL
Intervention: Biphasic calcium phosphate
Number of subjects: 56

Group type: COMPARATOR
Intervention: Deproteinized bovine bone
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Both graft materials
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 56
Study: 28046032

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo gas
Number of subjects: 43
Study: 25511347

Group type: COMPARATOR
Intervention: Fentanyl group (placebo)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Paracetamol group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Preemptive paracetamol group
Number of subjects: 60
Study: 23469685

Group type: EXPERIMENTAL
Intervention: ABCB1 haplotype (1236TT‐2677TT‐3435TT) carriers
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Homozygotes (AA) carriers of ABCG2 c.421C > A
Number of subjects: 12
Study: 21817105

Group type: EXPERIMENTAL
Intervention: Intravenous lipids
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control (no intravenous lipids)
Number of subjects: 102
Study: 19453924

Group type: COMPARATOR
Intervention: Omega-3
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16737370

Group type: EXPERIMENTAL
Intervention: Denial of responsibility
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Counterattitudinal behavior
Number of subjects: 3
Study: 12736088

Group type: EXPERIMENTAL
Intervention: D-cycloserine (daily oral dose of 50 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 10912746

Group type: EXPERIMENTAL
Intervention: 2 mg trandolapril once daily for 6 weeks
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: 50 mg losartan once daily for 6 weeks
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: SBPM
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: ABPM
Number of subjects: 229

Group type: COMPARATOR
Intervention: Office BP
Number of subjects: 229
Study: 9378688

Group type: EXPERIMENTAL
Intervention: Melatonin 10 mg q.d. at 10:00 p.m. for 12 weeks
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Melatonin withdrawal
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 5
Study: 7691784

Group type: EXPERIMENTAL
Intervention: Postoperative radiation therapy with concomitant mitomycin C
Number of subjects: 113

Group type: COMPARATOR
Intervention: Postoperative radiation therapy alone
Number of subjects: 113
Study: 3757322

Group type: EXPERIMENTAL
Intervention: NaHCO3 (22, 44 or 88 mEq/h)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: NaCl (22 or 44 mEq/h)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Dextrose 5% in water (30 mmol/h)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Acetate metabolism
Number of subjects: 10
Study: 31161045

Group type: EXPERIMENTAL
Intervention: Enhanced support intervention (ESI) delivered by community pharmacy team member over four months (4-6 sessions)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Enhanced support intervention (ESI)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Economic evaluation
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Process evaluation
Number of subjects: 100
Study: 30541585

Group type: EXPERIMENTAL
Intervention: Keeogo exoskeleton
Number of subjects: 29
Study: 27889723

Group type: EXPERIMENTAL
Intervention: 100,000 IU of oral cholecalciferol (vitamin D)
Number of subjects: 324

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Vitamin D
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Vitamin D and Placebo
Number of subjects: 324
Study: 25132872

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (two doses of 15 mg/kg preoperative and postoperative)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 22699418

Group type: EXPERIMENTAL
Intervention: Nilotinib 300 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nilotinib 400 mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Imatinib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nilotinib
Number of subjects: 0
Study: 20721517

Group type: EXPERIMENTAL
Intervention: Concomitant use of beta-blockers and dobutamine (Group C, n=11)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Suspension of beta-blockers to start dobutamine (Group B, n=25)
Number of subjects: 44

Group type: COMPARATOR
Intervention: No beta-blockers used (Group A, n=8)
Number of subjects: 44
Study: 18603572

Group type: EXPERIMENTAL
Intervention: Long-acting octreotide (30 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 9
Study: 15983792

Group type: EXPERIMENTAL
Intervention: Methylphenidate 5 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Methylphenidate 10 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Methylphenidate 20 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Methylphenidate 40 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 11874177

Group type: COMPARATOR
Intervention: GH alone (Saizen, Ares‐Serono, Geneva) 18 IU/m2/week (0.2 mg/kg/week)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: GH + Ox 0.1 mg/kg/day p.o.
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: GH + transient Ox
Number of subjects: 91